To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Overview

This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The total study duration will be up to approximately 109 weeks. Eligible participants will be assigned to one of four cohorts based upon their baseline CIDP treatment (Cohorts A and D - immunoglobulin [Ig] or plasma exchange [PLEX]; Cohort B - corticosteroids; Cohort C - naive or untreated in previous 3-24 months) and whether they meet diagnosis according to the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria (Cohorts A, B, and C) or clinical criteria only (Cohort D) at the time of screening.

Eligibility

Inclusion criteria:

All Cohorts:

1. Are >= 18 years at the Screening Visit.
2. Have met clinical diagnostic criteria for typical CIDP, or one of the following CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Clinical criteria for typical CIDP and variants are as follows (either criterion must be met):
   1. Typical CIDP: All the following:
      • Progressive or relapsing, symmetric, proximal, and distal muscle weakness of upper and lower limbs, and sensory involvement of at least two limbs (at any point in the disease course)
      • Developing over at least 8 weeks
      • Absent or reduced tendon reflexes in all limbs
   2. CIDP variants: One of the following, but otherwise as in typical CIDP (tendon

      reflexes may be normal in unaffected limbs):

      • Multifocal CIDP: documented sensory loss and muscle weakness in a multifocal pattern, usually asymmetric, upper limb predominant
      • Focal CIDP: sensory loss and muscle weakness in only one limb
      • Motor CIDP: motor symptoms and signs without sensory involvement

Cohorts A and B:

          3. Have electrodiagnostic test results supporting the diagnosis of CIDP in accordance
             with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP; for Cohorts A and B,
             either criterion must be met:
               1. Motor nerve conduction criteria strongly supportive of demyelination.
               2. Motor nerve conduction criteria weakly supportive of demyelination and 2 or more
                  of the following additional diagnostic criteria:
                    -  Objective improvement to an empiric trial of therapy with immunoglobulin
                       treatment, plasma exchange (PLEX), or corticosteroids.
                    -  Diagnostic imaging by ultrasound or magnetic resonance imaging (MRI)
                       supporting the diagnosis of CIDP by demonstrating nerve enlargement.
                    -  Cerebrospinal fluid (CSF) demonstrating albuminocytologic dissociation
                       (i.e., elevated CSF protein level [defined as > 70 milligrams per deciliter
                       {mg/dL} or > 10 mg/dL greater than years of age for those aged 60 years and
                       over] with normal CSF white blood cell [WBC] level).
                    -  Nerve biopsy demonstrating features supporting the diagnosis of CIDP, such
                       as edema, demyelination, and/or onion bulb formation.
             Cohort C only:
          4. Have a diagnosis of CIDP in accordance with the EAN/PNS Guideline on Diagnosis and
             Treatment of CIDP based on clinical criteria and motor nerve conduction criteria
             strongly supportive of demyelination (i.e., motor nerve conduction criteria weakly
             supportive of demyelination is insufficient diagnostic evidence for admission to
             Cohort C).
             Cohort D only:
          5. Have met only clinical diagnostic criteria for typical CIDP, or one of the following
             CIDP variants: multifocal CIDP, focal CIDP, or motor CIDP in accordance with the
             EAN/PNS Guideline on Diagnosis and Treatment of CIDP. Either inclusion criterion 2(a)
             or 2(b) must be met.
        Additional inclusion criteria are defined in the protocol.
        Exclusion Criteria:
        All Cohorts:
          1. Have current or prior history of immunoglobulin M (IgM) paraproteinemia with or
             without anti-myelin-associated-glycoprotein antibodies.
          2. Have Distal CIDP, Sensory CIDP or are suspected of having a diagnosis of auto-immune
             nodopathy in accordance with the EAN/PNS Guideline on Diagnosis and Treatment of CIDP.
          3. Have polyneuropathy of causes other than CIDP including but not limited to:
               1. Multifocal motor neuropathy
               2. Hereditary demyelinating neuropathy
               3. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change
                  syndromes (i.e., POEMS)
               4. Lumbosacral radiculoplexus neuropathy
               5. Systemic illnesses including vitamin deficiency syndromes and paraneoplastic
                  neuropathies
               6. Drug- or toxin-induced
          4. Have diabetes mellitus (DM) and meets any of the following criteria:
               1. Does not meet inclusion criteria 2(a) and 3(a).
               2. In the opinion of the Investigator, there is evidence of poorly controlled DM
                  preceding the diagnosis of CIDP.
               3. In the opinion of the Investigator, there is evidence of poorly controlled DM at
                  screening.
          5. Have a history of myelopathy or evidence of central demyelination.
          6. Are receiving chronic oral corticosteroids monotherapy at a dose > 40 mg/day
             prednisolone/prednisone or its equivalent at the Screening Visit.
          7. Are receiving chronic oral corticosteroid at a dose > 10 mg/day
             prednisolone/prednisone or equivalent in combination with immunoglobulin therapy or
             PLEX at the Screening Visit.
        Additional exclusion criteria are defined in the protocol.